How many drugs treat Osteitis deformans?

Drug Landscape tracks 10 marketed treatments for Osteitis deformans (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/osteitis-deformans.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Osteitis deformans — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteitis deformans (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteitis deformans, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Osteobios	CALCITONIN	Sanofi Aventis Us	Calcitonin [EPC]	calcitonin receptor	2025-01-01
Zometa	ZOLEDRONIC ACID	Novartis	zoledronic acid	Farnesyl pyrophosphate synthase	2001-01-01
Fosamax	ALENDRONIC ACID	Merck And Co Inc	Vitamin D [EPC]	Farnesyl pyrophosphate synthase	1995-01-01
Miacalcin	calcitonin (salmon synthetic)	Sanofi	Calcitonin [EPC]	calcitonin receptors	1978-01-01
Didronel	ETIDRONIC ACID	Procter And Gamble	Bisphosphonate		1977-01-01
Risedronate	Risedronate	Toronto Rehabilitation Institute		Butyrophilin subfamily 3 member A1, Farnesyl pyrophosphate synthase, Farnesyl diphosphate synthase
pamidronate	pamidronate	US Department of Veterans Affairs		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Hypoxanthine-guanine phosphoribosyltransferase
alendronate	alendronate	Massachusetts General Hospital		Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, Farnesyl pyrophosphate synthase, EC 2.5.1.1, EC 2.5.1.10
Zometa	Zometa	University of Arkansas		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase
Zoledronate	Zoledronate	Children's Hospital Medical Center, Cincinnati		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Osteitis deformans
Centre National d'Etudes Spatiales · 1 drug in Osteitis deformans
Children's Hospital Medical Center, Cincinnati · 1 drug in Osteitis deformans
Massachusetts General Hospital · 1 drug in Osteitis deformans
Merck And Co Inc · 1 drug in Osteitis deformans
Novartis · 1 drug in Osteitis deformans
Organon and Co · 1 drug in Osteitis deformans
Procter And Gamble · 1 drug in Osteitis deformans
Sanofi · 1 drug in Osteitis deformans
Sanofi Aventis Us · 1 drug in Osteitis deformans
Toronto Rehabilitation Institute · 1 drug in Osteitis deformans
US Department of Veterans Affairs · 1 drug in Osteitis deformans

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteitis deformans:

Cite this brief

Drug Landscape (2026). Osteitis deformans — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteitis-deformans. Accessed 2026-06-10.

Osteitis deformans full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing